How to Buy auropharma Shares on Fincept?
You can buy Aurobindo Pharma Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Aurobindo Pharma Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Auropharma, including updates on board meetings and corporate actions.
Aurobindo Pharma Limited - https://www.aurobindo.com
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Aurobindo Pharma Limited Share Price Today
1,165.00
OPEN
1,193.35
HIGH
1,159.60
LOW
1,183.15
CLOSE
1,020 K
VOLUME
73,132 Cr
Market Cap
1033461
Average Volume
Healthcare
Sector
NSI
Exchange
Aurobindo Pharma Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: AUROPHARMA Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Aurobindo Pharma Limited |
AUROPHARMA |
INE406A01029 |
Annual General Meeting |
26 Aug 2024 |
1 |
N/A |
Aurobindo Pharma Limited |
AUROPHARMA |
INE406A01029 |
Buy Back |
30 Jul 2024 |
1 |
N/A |
Aurobindo Pharma Limited |
AUROPHARMA |
INE406A01029 |
Interim Dividend - Rs 1.50 Per Share |
20 Feb 2024 |
1 |
N/A |
Aurobindo Pharma Limited |
AUROPHARMA |
INE406A01029 |
Interim Dividend - Rs 3 Per Share |
20 Nov 2023 |
1 |
N/A |
Aurobindo Pharma Limited |
AUROPHARMA |
INE406A01029 |
Annual General Meeting |
22 Aug 2023 |
1 |
N/A |
NSE: AUROPHARMA Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
AUROPHARMA |
06 Jan 2025, 10:51:58 |
Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
Pharmaceuticals |
AUROPHARMA |
28 Dec 2024, 14:46:37 |
Updates |
Pharmaceuticals |
AUROPHARMA |
27 Dec 2024, 17:37:55 |
Loss/Duplicate-Share Certificate-XBRL |
Pharmaceuticals |
AUROPHARMA |
27 Dec 2024, 17:35:12 |
Loss of Share Certificates |
Pharmaceuticals |
AUROPHARMA |
25 Dec 2024, 15:48:00 |
Trading Window-XBRL |
Pharmaceuticals |
NSE: AUROPHARMA Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Aurobindo Pharma Limited |
AUROPHARMA |
15 Oct 2024, 15:38:00 |
15 Oct 2024, 15:38:00 |
|
Aurobindo Pharma Limited |
AUROPHARMA |
16 Jul 2024, 14:22:00 |
16 Jul 2024, 14:22:00 |
|
Aurobindo Pharma Limited |
AUROPHARMA |
05 Apr 2024, 12:20:00 |
05 Apr 2024, 12:45:00 |
|
Aurobindo Pharma Limited |
AUROPHARMA |
19 Jan 2024, 18:45:00 |
19 Jan 2024, 19:15:00 |
|
Aurobindo Pharma Limited |
AUROPHARMA |
11 Oct 2023, 09:46:00 |
11 Oct 2023, 10:15:00 |
NSE: AUROPHARMA Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Independent Director,Chairperson & Non-Executive Director |
13 Jun 1961 |
01 Apr 2024 |
03628755 |
Mangalam Ramasubramanian Kumar |
Active |
Executive Director-MD |
01 May 1958 |
26 Dec 1986 |
01284195 |
Nityananda Reddy Kambam |
Active |
Executive Director |
01 Jun 1960 |
18 Sep 2006 |
01284266 |
Madan Mohan Reddy Mettu |
Active |
Non-Executive Director |
30 Apr 1958 |
26 Dec 1986 |
01284132 |
Venkata Ramprasad Reddy Penaka |
Active |
Non-Executive Director |
22 Feb 1985 |
27 Sep 2007 |
01628013 |
Sarath Chandra Reddy Penaka |
Active |
NSE: AUROPHARMA Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
AUROPHARMA |
N/A |
INE406A01029 |
Aurobindo Pharma Limited |
01 Nov 2024, 16:30:25 |
Financial Results |
AUROPHARMA |
N/A |
INE406A01029 |
Aurobindo Pharma Limited |
31 Jul 2024, 09:52:45 |
AUROBINDO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 18-Jul-2024 to consider Buyback. |
AUROPHARMA |
N/A |
INE406A01029 |
Aurobindo Pharma Limited |
14 Jul 2024, 20:32:54 |
AUROBINDO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 25-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2024 . |
AUROPHARMA |
N/A |
INE406A01029 |
Aurobindo Pharma Limited |
16 May 2024, 15:01:45 |
Financial Results |
AUROPHARMA |
N/A |
INE406A01029 |
Aurobindo Pharma Limited |
01 Feb 2024, 16:29:02 |
NSE: AUROPHARMA Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
AUROPHARMA |
- |
INE406A01029 |
Aurobindo Pharma Limited |
01 Nov 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results |
AUROPHARMA |
- |
INE406A01029 |
Aurobindo Pharma Limited |
31 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Buyback |
AUROPHARMA |
- |
INE406A01029 |
Aurobindo Pharma Limited |
14 Jul 2024, 00:00:00 |
To consider buyback for equity shares |
Financial Results |
AUROPHARMA |
- |
INE406A01029 |
Aurobindo Pharma Limited |
16 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 |
Financial Results |
AUROPHARMA |
- |
INE406A01029 |
Aurobindo Pharma Limited |
01 Feb 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 |
NSE: AUROPHARMA Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Pension And Other Postretirement Benefit Plans | Tradeand Other Payables Non Current | Non Current Deferred Revenue | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Deferred Taxes Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Defined Pension Benefit | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Investmentin Financial Assets | Held To Maturity Securities | Available For Sale Securities | Financial Assets Designatedas Fair Value Through Profitor Loss | Trading Securities | Long Term Equity Investment | Investmentsin Joint Venturesat Cost | Investmentsin Associatesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Assets Held For Sale Current | Restricted Cash | Prepaid Assets | Inventory | Inventories Adjustments Allowances | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 580,801,623.00 | 580,801,623.00 | 41,869,000,000.00 | 84,272,500,000.00 | 268,698,300,000.00 | 389,692,600,000.00 | 118,850,600,000.00 | 268,698,300,000.00 | 3,363,800,000.00 | 308,783,900,000.00 | 328,263,800,000.00 | 308,849,600,000.00 | 65,700,000.00 | 308,783,900,000.00 | 308,203,100,000.00 | 0.00 | 0.00 | 580,800,000.00 | 580,800,000.00 | 172,094,900,000.00 | 28,689,100,000.00 | 456,100,000.00 | 0.00 | 0.00 | 0.00 | 3,706,900,000.00 | 21,909,400,000.00 | 2,429,500,000.00 | 19,479,900,000.00 | 2,473,700,000.00 | 143,405,800,000.00 | 6,691,900,000.00 | 0.00 | 62,363,100,000.00 | 934,300,000.00 | 61,428,800,000.00 | 0.00 | 3,045,800,000.00 | 47,967,600,000.00 | 0.00 | 0.00 | 3,636,300,000.00 | 44,331,300,000.00 | 480,944,500,000.00 | 218,688,100,000.00 | 2,607,600,000.00 | 0.00 | 0.00 | 12,033,100,000.00 | 7,187,600,000.00 | 0.00 | 7,187,600,000.00 | 0.00 | 0.00 | 898,900,000.00 | 0.00 | 0.00 | 40,085,600,000.00 | 33,785,700,000.00 | 6,299,900,000.00 | 149,241,300,000.00 | 0.00 | 149,241,300,000.00 | 34,966,000,000.00 | 114,275,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 262,256,400,000.00 | 28,690,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104,318,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 138,800,000.00 | 0.00 | 53,882,800,000.00 | 0.00 | 0.00 | 75,225,600,000.00 | 36,185,900,000.00 | 39,039,700,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 585,938,609.00 | 585,938,609.00 | 29,217,400,000.00 | 66,476,300,000.00 | 257,661,900,000.00 | 361,580,200,000.00 | 120,065,000,000.00 | 257,661,900,000.00 | 3,324,100,000.00 | 298,428,000,000.00 | 319,777,000,000.00 | 298,508,000,000.00 | 80,000,000.00 | 298,428,000,000.00 | 297,842,100,000.00 | 268,014,200,000.00 | 5,295,100,000.00 | 585,900,000.00 | 585,900,000.00 | 152,207,100,000.00 | 30,215,800,000.00 | 364,700,000.00 | 2,257,000,000.00 | 1,200,000.00 | 363,500,000.00 | 3,565,600,000.00 | 23,874,300,000.00 | 2,525,300,000.00 | 21,349,000,000.00 | 2,257,000,000.00 | 121,991,300,000.00 | 2,803,300,000.00 | 2,490,100,000.00 | 42,602,000,000.00 | 798,800,000.00 | 41,803,200,000.00 | 2,567,900,000.00 | 2,567,900,000.00 | 55,648,300,000.00 | 11,076,500,000.00 | 30,200,000.00 | 2,490,100,000.00 | 44,541,600,000.00 | 450,715,100,000.00 | 208,658,800,000.00 | 2,299,600,000.00 | 10,800,000.00 | 5,819,300,000.00 | 12,126,400,000.00 | 1,516,100,000.00 | 893,400,000.00 | 471,200,000.00 | 151,500,000.00 | 0.00 | 1,700,500,000.00 | 1,603,300,000.00 | 97,200,000.00 | 40,766,100,000.00 | 34,814,600,000.00 | 5,951,500,000.00 | 144,116,900,000.00 | -63,726,900,000.00 | 207,843,800,000.00 | 28,661,800,000.00 | 115,455,100,000.00 | 120,234,900,000.00 | 49,160,600,000.00 | 9,786,500,000.00 | 0.00 | 242,056,300,000.00 | 25,364,300,000.00 | 34,500,000.00 | 4,337,100,000.00 | 37,100,000.00 | 22,857,600,000.00 | 98,082,300,000.00 | -22,400,000.00 | 4,683,300,000.00 | 45,609,500,000.00 | 15,770,300,000.00 | 32,041,600,000.00 | 5,278,400,000.00 | 56,700,000.00 | 48,167,400,000.00 | -1,232,500,000.00 | 49,399,900,000.00 | 63,251,700,000.00 | 29,316,900,000.00 | 33,934,800,000.00 | 20,115,700,000.00 | 13,819,100,000.00 |
| 2024-03-31T00:00:00 | annual | 585,938,609.00 | 585,938,609.00 | 29,217,400,000.00 | 66,476,300,000.00 | 257,661,900,000.00 | 361,580,200,000.00 | 120,065,000,000.00 | 257,661,900,000.00 | 3,324,100,000.00 | 298,428,000,000.00 | 319,777,000,000.00 | 298,508,000,000.00 | 80,000,000.00 | 298,428,000,000.00 | 297,842,100,000.00 | 268,014,200,000.00 | 5,295,100,000.00 | 585,900,000.00 | 585,900,000.00 | 152,207,100,000.00 | 30,215,800,000.00 | 364,700,000.00 | 2,257,000,000.00 | 1,200,000.00 | 363,500,000.00 | 3,565,600,000.00 | 23,874,300,000.00 | 2,525,300,000.00 | 21,349,000,000.00 | 2,257,000,000.00 | 121,991,300,000.00 | 2,803,300,000.00 | 2,490,100,000.00 | 42,602,000,000.00 | 798,800,000.00 | 41,803,200,000.00 | 2,567,900,000.00 | 2,567,900,000.00 | 55,648,300,000.00 | 11,076,500,000.00 | 30,200,000.00 | 2,490,100,000.00 | 44,541,600,000.00 | 450,715,100,000.00 | 208,658,800,000.00 | 2,299,600,000.00 | 10,800,000.00 | 5,819,300,000.00 | 12,126,400,000.00 | 1,516,100,000.00 | 893,400,000.00 | 471,200,000.00 | 151,500,000.00 | 0.00 | 1,700,500,000.00 | 1,603,300,000.00 | 97,200,000.00 | 40,766,100,000.00 | 34,814,600,000.00 | 5,951,500,000.00 | 144,116,900,000.00 | -63,726,900,000.00 | 207,843,800,000.00 | 28,661,800,000.00 | 115,455,100,000.00 | 120,234,900,000.00 | 49,160,600,000.00 | 9,786,500,000.00 | 0.00 | 242,056,300,000.00 | 25,364,300,000.00 | 34,500,000.00 | 4,337,100,000.00 | 37,100,000.00 | 22,857,600,000.00 | 98,082,300,000.00 | -22,400,000.00 | 4,683,300,000.00 | 45,609,500,000.00 | 15,770,300,000.00 | 32,041,600,000.00 | 5,278,400,000.00 | 56,700,000.00 | 48,167,400,000.00 | -1,232,500,000.00 | 49,399,900,000.00 | 63,251,700,000.00 | 29,316,900,000.00 | 33,934,800,000.00 | 20,115,700,000.00 | 13,819,100,000.00 |
| 2023-09-30T00:00:00 | quarterly | 585,938,609.00 | 585,938,609.00 | 21,132,200,000.00 | 66,486,300,000.00 | 243,546,400,000.00 | 344,341,300,000.00 | 105,431,800,000.00 | 243,546,400,000.00 | 4,033,000,000.00 | 281,888,000,000.00 | 298,970,800,000.00 | 281,945,100,000.00 | 57,100,000.00 | 281,888,000,000.00 | 281,302,100,000.00 | 0.00 | 0.00 | 585,900,000.00 | 585,900,000.00 | 157,290,800,000.00 | 27,171,100,000.00 | 270,900,000.00 | 0.00 | 0.00 | 0.00 | 4,307,900,000.00 | 20,299,700,000.00 | 3,216,900,000.00 | 17,082,800,000.00 | 2,120,000,000.00 | 130,119,700,000.00 | 10,805,400,000.00 | 0.00 | 46,186,600,000.00 | 816,100,000.00 | 45,370,500,000.00 | 0.00 | 1,691,200,000.00 | 48,534,500,000.00 | 0.00 | 0.00 | 3,480,600,000.00 | 45,053,900,000.00 | 439,235,900,000.00 | 203,684,400,000.00 | 9,529,000,000.00 | 0.00 | 0.00 | 9,829,000,000.00 | 5,317,100,000.00 | 0.00 | 5,317,100,000.00 | 0.00 | 0.00 | 1,027,200,000.00 | 0.00 | 0.00 | 38,341,600,000.00 | 32,412,600,000.00 | 5,929,000,000.00 | 136,683,000,000.00 | 0.00 | 136,683,000,000.00 | 57,983,600,000.00 | 78,699,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 235,551,500,000.00 | 21,573,300,000.00 | 0.00 | 29,100,000.00 | 0.00 | 0.00 | 92,823,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 132,600,000.00 | 227,700,000.00 | 46,395,800,000.00 | 0.00 | 0.00 | 74,369,700,000.00 | 33,048,600,000.00 | 41,321,100,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 585,938,609.00 | 585,938,609.00 | 4,652,300,000.00 | 52,862,100,000.00 | 229,179,300,000.00 | 317,013,700,000.00 | 100,518,900,000.00 | 229,179,300,000.00 | 4,246,900,000.00 | 268,398,500,000.00 | 274,588,100,000.00 | 268,518,500,000.00 | 120,000,000.00 | 268,398,500,000.00 | 267,812,600,000.00 | 240,130,300,000.00 | 4,268,900,000.00 | 585,900,000.00 | 585,900,000.00 | 130,381,400,000.00 | 15,443,600,000.00 | -15,153,200,000.00 | 1,727,200,000.00 | 290,400,000.00 | 0.00 | 3,896,100,000.00 | 9,404,900,000.00 | 3,215,300,000.00 | 6,189,600,000.00 | 1,727,200,000.00 | 114,937,800,000.00 | 2,235,900,000.00 | 2,116,000,000.00 | 43,457,200,000.00 | 1,031,600,000.00 | 42,425,600,000.00 | 2,005,300,000.00 | 2,005,300,000.00 | 47,554,600,000.00 | 8,816,600,000.00 | 24,900,000.00 | 2,116,000,000.00 | 38,713,100,000.00 | 398,899,900,000.00 | 183,443,200,000.00 | 45,300,000.00 | 45,300,000.00 | 4,766,100,000.00 | 6,774,900,000.00 | 2,281,600,000.00 | 1,511,500,000.00 | 618,600,000.00 | 151,500,000.00 | 1,511,500,000.00 | 1,683,600,000.00 | 1,587,900,000.00 | 95,700,000.00 | 39,219,200,000.00 | 33,258,500,000.00 | 5,960,700,000.00 | 128,036,000,000.00 | -55,593,500,000.00 | 183,629,500,000.00 | 48,082,200,000.00 | 79,953,800,000.00 | 90,081,700,000.00 | 35,920,400,000.00 | 9,545,200,000.00 | 0.00 | 215,456,700,000.00 | 18,687,000,000.00 | 191,400,000.00 | 857,600,000.00 | 115,700,000.00 | 16,799,600,000.00 | 85,112,300,000.00 | -48,800,000.00 | 3,784,800,000.00 | 37,272,900,000.00 | 14,068,300,000.00 | 30,035,100,000.00 | 5,480,000,000.00 | 756,200,000.00 | 44,663,800,000.00 | -1,216,600,000.00 | 45,880,400,000.00 | 62,236,300,000.00 | 18,273,400,000.00 | 43,962,900,000.00 | 25,931,300,000.00 | 18,031,600,000.00 |
| 2023-03-31T00:00:00 | annual | 585,938,609.00 | 585,938,609.00 | 4,652,300,000.00 | 52,862,100,000.00 | 229,179,300,000.00 | 317,013,700,000.00 | 100,518,900,000.00 | 229,179,300,000.00 | 4,246,900,000.00 | 268,398,500,000.00 | 274,588,100,000.00 | 268,518,500,000.00 | 120,000,000.00 | 268,398,500,000.00 | 267,812,600,000.00 | 240,130,300,000.00 | 4,268,900,000.00 | 585,900,000.00 | 585,900,000.00 | 130,381,400,000.00 | 15,443,600,000.00 | -15,153,200,000.00 | 1,727,200,000.00 | 290,400,000.00 | 0.00 | 3,896,100,000.00 | 9,404,900,000.00 | 3,215,300,000.00 | 6,189,600,000.00 | 1,727,200,000.00 | 114,937,800,000.00 | 2,235,900,000.00 | 2,116,000,000.00 | 43,457,200,000.00 | 1,031,600,000.00 | 42,425,600,000.00 | 2,005,300,000.00 | 2,005,300,000.00 | 47,554,600,000.00 | 8,816,600,000.00 | 24,900,000.00 | 2,116,000,000.00 | 38,713,100,000.00 | 398,899,900,000.00 | 183,443,200,000.00 | 45,300,000.00 | 45,300,000.00 | 4,766,100,000.00 | 6,774,900,000.00 | 2,281,600,000.00 | 1,511,500,000.00 | 618,600,000.00 | 151,500,000.00 | 1,511,500,000.00 | 1,683,600,000.00 | 1,587,900,000.00 | 95,700,000.00 | 39,219,200,000.00 | 33,258,500,000.00 | 5,960,700,000.00 | 128,036,000,000.00 | -55,593,500,000.00 | 183,629,500,000.00 | 48,082,200,000.00 | 79,953,800,000.00 | 90,081,700,000.00 | 35,920,400,000.00 | 9,545,200,000.00 | 0.00 | 215,456,700,000.00 | 18,687,000,000.00 | 191,400,000.00 | 857,600,000.00 | 115,700,000.00 | 16,799,600,000.00 | 85,112,300,000.00 | -48,800,000.00 | 3,784,800,000.00 | 37,272,900,000.00 | 14,068,300,000.00 | 30,035,100,000.00 | 5,480,000,000.00 | 756,200,000.00 | 44,663,800,000.00 | -1,216,600,000.00 | 45,880,400,000.00 | 62,236,300,000.00 | 18,273,400,000.00 | 43,962,900,000.00 | 25,931,300,000.00 | 18,031,600,000.00 |
| 2022-03-31T00:00:00 | annual | 585,938,609.00 | 585,938,609.00 | 0.00 | 32,789,600,000.00 | 209,626,900,000.00 | 273,764,400,000.00 | 99,667,100,000.00 | 209,626,900,000.00 | 4,785,000,000.00 | 245,759,800,000.00 | 248,251,900,000.00 | 245,740,500,000.00 | -19,300,000.00 | 245,759,800,000.00 | 245,173,900,000.00 | 225,190,100,000.00 | 4,268,900,000.00 | 585,900,000.00 | 585,900,000.00 | 93,476,700,000.00 | 11,916,900,000.00 | 297,700,000.00 | 1,717,900,000.00 | 297,700,000.00 | 0.00 | 4,109,600,000.00 | 5,678,200,000.00 | 3,186,100,000.00 | 2,492,100,000.00 | 1,717,900,000.00 | 81,559,800,000.00 | 1,279,400,000.00 | 580,300,000.00 | 27,111,400,000.00 | 1,598,900,000.00 | 25,512,500,000.00 | 1,705,600,000.00 | 1,705,600,000.00 | 33,869,700,000.00 | 6,813,500,000.00 | 25,700,000.00 | 580,300,000.00 | 27,030,500,000.00 | 339,217,200,000.00 | 157,990,300,000.00 | 100,000.00 | 0.00 | 1,461,200,000.00 | 2,885,900,000.00 | 3,327,400,000.00 | 0.00 | 915,900,000.00 | 151,500,000.00 | 2,260,000,000.00 | 2,855,600,000.00 | 2,748,000,000.00 | 107,600,000.00 | 36,132,900,000.00 | 31,378,700,000.00 | 4,754,200,000.00 | 107,699,100,000.00 | -38,680,300,000.00 | 146,379,400,000.00 | 30,414,800,000.00 | 6,992,600,000.00 | 79,741,900,000.00 | 28,410,900,000.00 | 7,811,800,000.00 | 0.00 | 181,226,900,000.00 | 15,550,100,000.00 | 320,200,000.00 | 791,000,000.00 | 112,200,000.00 | 12,319,700,000.00 | 75,538,500,000.00 | 0.00 | 3,402,700,000.00 | 33,545,500,000.00 | 11,978,400,000.00 | 26,611,900,000.00 | 3,746,400,000.00 | 2,699,900,000.00 | 40,122,600,000.00 | -921,300,000.00 | 41,043,900,000.00 | 45,576,400,000.00 | 3,951,300,000.00 | 41,625,100,000.00 | 6,297,200,000.00 | 35,327,900,000.00 |
| 2021-03-31T00:00:00 | annual | 585,938,609.00 | 585,938,609.00 | 0.00 | 53,390,800,000.00 | 188,102,700,000.00 | 269,021,400,000.00 | 91,584,600,000.00 | 188,102,700,000.00 | 3,668,100,000.00 | 219,298,700,000.00 | 220,983,600,000.00 | 219,289,900,000.00 | -8,800,000.00 | 219,298,700,000.00 | 218,712,700,000.00 | 201,367,600,000.00 | 4,268,900,000.00 | 585,900,000.00 | 585,900,000.00 | 119,250,000,000.00 | 12,599,500,000.00 | 395,000,000.00 | 1,571,100,000.00 | 395,000,000.00 | 0.00 | 5,745,600,000.00 | 4,346,800,000.00 | 2,661,900,000.00 | 1,684,900,000.00 | 1,571,200,000.00 | 106,650,500,000.00 | 5,561,900,000.00 | 2,103,500,000.00 | 49,044,000,000.00 | 1,006,200,000.00 | 48,037,800,000.00 | 1,719,300,000.00 | 1,719,300,000.00 | 27,946,800,000.00 | 8,535,000,000.00 | 26,000,000.00 | 2,103,600,000.00 | 27,946,800,000.00 | 338,539,900,000.00 | 140,304,800,000.00 | 4,326,500,000.00 | 0.00 | 5,098,400,000.00 | 4,526,800,000.00 | 4,798,200,000.00 | 0.00 | 4,798,200,000.00 | 151,500,000.00 | 1,540,000,000.00 | 947,000,000.00 | 2,620,700,000.00 | 0.00 | 31,196,000,000.00 | 26,907,000,000.00 | 4,289,000,000.00 | 93,155,100,000.00 | -31,457,100,000.00 | 93,155,100,000.00 | 24,288,900,000.00 | 68,866,200,000.00 | 67,542,500,000.00 | 24,176,800,000.00 | 2,860,100,000.00 | 0.00 | 198,235,100,000.00 | 14,488,100,000.00 | 198,200,000.00 | 836,100,000.00 | 128,700,000.00 | 9,650,000,000.00 | 90,265,700,000.00 | 0.00 | 3,549,800,000.00 | 41,186,300,000.00 | 13,024,800,000.00 | 32,504,800,000.00 | 5,121,800,000.00 | 789,800,000.00 | 35,032,800,000.00 | -949,900,000.00 | 35,982,700,000.00 | 56,212,000,000.00 | 2,477,300,000.00 | 53,734,700,000.00 | 6,500,000.00 | 53,728,200,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 31,621,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: AUROPHARMA Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Payments | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Sale Of Business | Purchase Of Business | Net Intangibles Purchase And Sale | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Gain Loss On Sale Of Business | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -11,269,800,000.00 | -171,700,000.00 | 15,632,400,000.00 | 0.00 | -35,615,000,000.00 | 33,854,300,000.00 | 0.00 | 43,922,700,000.00 | 141,700,000.00 | -10,210,100,000.00 | 8,004,200,000.00 | 0.00 | -2,506,500,000.00 | -2,636,400,000.00 | 0.00 | 0.00 | 0.00 | 14,613,100,000.00 | -847,600,000.00 | 0.00 | 15,460,700,000.00 | -171,700,000.00 | 15,632,400,000.00 | -42,559,500,000.00 | -11,890,200,000.00 | 2,808,400,000.00 | 0.00 | 1,753,900,000.00 | 1,791,500,000.00 | -37,600,000.00 | -219,400,000.00 | 0.00 | 0.00 | -7,811,700,000.00 | -7,811,700,000.00 | -27,200,500,000.00 | 602,800,000.00 | -27,803,300,000.00 | 24,345,200,000.00 | -17,666,400,000.00 | -16,750,700,000.00 | 539,800,000.00 | -8,418,800,000.00 | 5,828,400,000.00 | -13,036,800,000.00 | -2,648,800,000.00 | -277,200,000.00 | 232,800,000.00 | 14,919,100,000.00 | 5,737,700,000.00 | 9,181,400,000.00 | -28,000,000.00 | -511,400,000.00 | -234,900,000.00 | 0.00 | 43,799,900,000.00 |
| 2023-03-31T00:00:00 | annual | -3,336,500,000.00 | -56,500,000.00 | 3,935,800,000.00 | 0.00 | -27,204,000,000.00 | 43,922,700,000.00 | 64,100,000.00 | 41,625,100,000.00 | -600,000.00 | 2,234,100,000.00 | 18,144,100,000.00 | 0.00 | -1,112,000,000.00 | -4,395,300,000.00 | -4,395,300,000.00 | 0.00 | 0.00 | 24,576,100,000.00 | 20,696,800,000.00 | 0.00 | 3,879,300,000.00 | -56,500,000.00 | 3,935,800,000.00 | -39,777,500,000.00 | -16,608,400,000.00 | 1,466,200,000.00 | 0.00 | 3,373,700,000.00 | 23,514,700,000.00 | -20,141,000,000.00 | -915,900,000.00 | 1,053,800,000.00 | -1,969,700,000.00 | -3,166,000,000.00 | -3,166,000,000.00 | -23,927,100,000.00 | 110,900,000.00 | -24,038,000,000.00 | 23,867,500,000.00 | -7,172,400,000.00 | -10,949,800,000.00 | 1,087,500,000.00 | -5,753,600,000.00 | 7,076,500,000.00 | -9,267,000,000.00 | -4,310,700,000.00 | -299,600,000.00 | 524,500,000.00 | 12,445,800,000.00 | 4,112,900,000.00 | 8,332,900,000.00 | -191,400,000.00 | 3,104,600,000.00 | -132,300,000.00 | 0.00 | 26,125,000,000.00 |
| 2022-03-31T00:00:00 | annual | 23,118,400,000.00 | 0.00 | 827,300,000.00 | 0.00 | -27,046,400,000.00 | 41,625,100,000.00 | -32,500,000.00 | 53,299,100,000.00 | 2,000,000.00 | -11,643,500,000.00 | -29,692,700,000.00 | 0.00 | -185,000,000.00 | -2,637,000,000.00 | -2,637,000,000.00 | 0.00 | 0.00 | -25,539,300,000.00 | -26,366,600,000.00 | -26,366,600,000.00 | 827,300,000.00 | 0.00 | 827,300,000.00 | -32,115,600,000.00 | 749,300,000.00 | 252,600,000.00 | 0.00 | -3,633,000,000.00 | 4,616,500,000.00 | -8,249,500,000.00 | -6,247,500,000.00 | 292,900,000.00 | -6,540,400,000.00 | -6,517,300,000.00 | -6,517,300,000.00 | -16,719,700,000.00 | 3,809,400,000.00 | -20,529,100,000.00 | 50,164,800,000.00 | -12,581,900,000.00 | 15,578,000,000.00 | 3,328,100,000.00 | 105,900,000.00 | 1,106,500,000.00 | 14,975,200,000.00 | -4,082,900,000.00 | 122,800,000.00 | -61,100,000.00 | 11,265,200,000.00 | 3,286,600,000.00 | 7,978,600,000.00 | -611,000,000.00 | 1,049,700,000.00 | 1,350,200,000.00 | 26,500,000.00 | 33,727,400,000.00 |
| 2021-03-31T00:00:00 | annual | 14,552,400,000.00 | -11,359,400,000.00 | 1,769,800,000.00 | 0.00 | -18,738,100,000.00 | 53,299,100,000.00 | 224,100,000.00 | 27,468,200,000.00 | -21,200,000.00 | 25,628,000,000.00 | -13,649,400,000.00 | 0.00 | -493,500,000.00 | -2,343,100,000.00 | 0.00 | 0.00 | 0.00 | -9,589,600,000.00 | -6,678,200,000.00 | -6,678,200,000.00 | -2,911,400,000.00 | -4,681,200,000.00 | 1,769,800,000.00 | 5,986,900,000.00 | -271,100,000.00 | 191,500,000.00 | 0.00 | -3,137,800,000.00 | 0.00 | -3,137,800,000.00 | 27,460,700,000.00 | 31,739,100,000.00 | -4,278,400,000.00 | -4,358,700,000.00 | -4,358,700,000.00 | -13,897,700,000.00 | 481,700,000.00 | -14,379,400,000.00 | 33,290,500,000.00 | -12,852,500,000.00 | -10,666,500,000.00 | -1,474,700,000.00 | 94,900,000.00 | 1,265,400,000.00 | -16,217,400,000.00 | 7,401,400,000.00 | -162,000,000.00 | -291,200,000.00 | 10,553,900,000.00 | 2,537,800,000.00 | 8,016,100,000.00 | -198,200,000.00 | -834,700,000.00 | 1,411,200,000.00 | -32,495,000,000.00 | 73,435,900,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 1,900,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -127,900,000.00 | 0.00 | 0.00 | -1,756,100,000.00 | 1,900,000.00 | 1,900,000.00 | 0.00 | 0.00 | -13,129,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103,500,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: AUROPHARMA Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Impairment Of Capital Assets | Restructuring And Mergern Acquisition | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Research And Development | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -65.46 | 0.00 | 6,376.74 | -236.75 | -236.75 | 3,172.97 | 1,491.91 | 13,236.21 | 6,139.99 | 4,648.08 | -3.95 | 268.09 | 285.76 | 3,344.26 | 3,172.97 | 24,313.79 | 120.42 | 58.59 | 58.59 | 0.00 | 0.00 | 3,172.97 | 3,172.97 | 0.00 | 3,172.97 | 4.00 | 3,168.97 | 3,168.97 | 1,211.02 | 4,379.99 | 205.72 | -236.75 | -154.09 | 229.81 | 62.37 | 98.66 | -3.95 | 21.62 | 268.09 | 285.76 | 4,390.71 | 11,077.58 | 3,259.73 | 1,491.91 | 573.77 | 918.14 | 75.63 | 2,502.41 | 1,684.72 | 817.69 | 120.42 | 15,468.29 | 13,236.21 | 28,704.50 | 28,704.50 |
| 2023-03-31T00:00:00 | annual | -2.81 | 0.00 | 3,996.76 | -10.73 | -10.73 | 1,927.50 | 1,244.58 | 11,899.70 | 3,986.03 | 2,741.45 | 5.41 | 128.95 | 145.89 | 1,935.42 | 1,927.50 | 22,079.53 | 133.76 | 58.59 | 58.59 | 0.00 | 0.00 | 1,927.50 | 1,927.50 | 0.00 | 1,927.50 | -0.15 | 1,927.65 | 1,927.65 | 684.85 | 2,612.50 | 128.84 | -10.73 | -13.23 | 0.00 | 23.96 | 0.00 | 5.41 | 11.53 | 128.95 | 145.89 | 2,537.60 | 10,179.83 | 3,128.80 | 1,244.58 | 411.29 | 833.29 | 39.51 | 2,348.17 | 1,685.76 | 662.41 | 133.76 | 12,717.43 | 11,899.70 | 24,617.13 | 24,617.13 |
| 2022-03-31T00:00:00 | annual | -12.97 | 0.00 | 4,652.31 | -116.21 | -116.21 | 2,648.15 | 1,126.52 | 10,815.18 | 4,536.10 | 3,409.58 | -17.04 | 36.84 | 31.60 | 2,751.39 | 2,648.15 | 20,066.28 | 124.19 | 58.59 | 58.59 | 0.00 | 0.00 | 2,648.15 | 2,648.15 | 0.00 | 2,648.15 | 1.04 | 2,647.11 | 2,647.11 | 725.63 | 3,372.74 | 134.56 | -116.21 | -76.01 | -2.23 | 192.22 | 0.00 | -17.04 | 11.80 | 36.84 | 31.60 | 3,300.27 | 9,251.10 | 2,394.97 | 1,126.52 | 328.66 | 797.86 | 65.24 | 2,177.02 | 1,496.67 | 680.35 | 124.19 | 12,551.37 | 10,815.18 | 23,366.55 | 23,366.55 |
| 2021-03-31T00:00:00 | annual | 681.43 | 0.00 | 5,378.33 | 3,080.22 | 2,645.30 | 5,334.84 | 1,055.39 | 10,611.08 | 8,458.55 | 7,403.16 | -52.12 | 59.57 | 22.37 | 3,805.89 | 5,334.84 | 20,081.53 | 122.54 | 58.59 | 58.59 | 0.00 | 0.00 | 5,334.83 | 5,334.83 | 0.01 | 5,334.84 | 1.02 | 5,333.82 | 5,333.82 | 2,009.77 | 7,343.59 | 225.78 | 2,645.30 | -2,955.53 | 28.16 | 0.00 | -152.85 | -52.12 | 14.92 | 59.57 | 22.37 | 4,476.41 | 9,470.45 | 2,474.51 | 1,055.39 | 253.78 | 801.61 | 68.81 | 2,429.72 | 1,564.17 | 865.55 | 122.54 | 13,946.86 | 10,611.08 | 24,557.94 | 24,557.94 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
4/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
61.34
P/E
20.52739
P/B
2.380777
Dividend Yield
0.36%
Market Cap
73,131.68 Cr.
Face Value
528.882
Book Value
528.882
ROE
11.82%
EBITDA Growth
6,395.23 Cr.
Debt/Equity
27.286
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of auropharma?
The market capitalization of Aurobindo Pharma Limited is ₹73,132 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Aurobindo Pharma Limited?
The PE and PB ratios of Aurobindo Pharma Limited are Not Available and 2.380777 respectively as of 05 Feb 2025.
What is the 52 Week High of Aurobindo Pharma Limited?
The 52-week high of Aurobindo Pharma Limited is ₹1592 as of 05 Feb 2025.
What is the 52 Week Low of Aurobindo Pharma Limited?
The 52-week low of Aurobindo Pharma Limited is ₹958.5 as of 05 Feb 2025.
What are the earnings per share (EPS) for Aurobindo Pharma Limited?
The Earnings Per Share (EPS) of Aurobindo Pharma Limited is ₹61.34 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Aurobindo Pharma Limited?
The Return on Equity (ROE) of Aurobindo Pharma Limited is 11.82% as per the most recent financial year data. Explore more on Fincept.